This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to DLL4. It is a humanized monoclonal antibody designed for the treatment of cancer.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
DrugMonitor™ Anti-Demcizumab Antibody (VS-1224-YC348)Demcizumab is in clinical investigation for treating nonsquamous non-small cell lung cancer. The DrugMonitor™ Anti-Demcizumab Antibody (VS-1224-YC348) is an anti-drug antibody (ADA) against Demcizumab. This drug-based antibody is raised in mice immunized with the Demcizumab. The anti-Demcizumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Demcizumab in samples.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-204 | Anti-Human DLL4 Recombinant Antibody (TAB-204) | ELISA, FC, IP, FuncS, IF, Neut, WB | IgG2 - kappa |
There are currently no Customer reviews or questions for AFC-TAB-204. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.